|
|
|
|
|
Protein depletion in Thai patients with hip fractures. |
2550 |
# |
|
|
|
|
|
Protein A/G-based immunochromatographic test for serodiagnosis of pythiosis in human and animal subjects from Asia and Americas |
2559 |
# |
|
|
|
|
|
Protective roles of trigonelline against oxalate-induced epithelial-to-mesenchymal transition in renal tubular epithelial cells: An in vitro study |
2563 |
# |
|
|
|
|
|
Protective role of N-trans-feruloyltyramine against beta-amyloid peptide-induced neurotoxicity in rat cultured cortical neurons |
2555 |
# |
|
|
|
|
|
Protective effects of novel derivatives of vitamin D 3 and lumisterol against UVB-induced damage in human keratinocytes involve activation of Nrf2 and p53 defense mechanisms |
2562 |
# |
|
|
|
|
|
Protective Effects of Mangosteen Extract on H2O2-Induced Cytotoxicity in SK-N-SH Cells and Scopolamine-Induced Memory Impairment in Mice |
2556 |
# |
|
|
|
|
|
Protective effects of finasteride against testosterone-induced calcium oxalate crystallization and crystal-cell adhesion. |
2562 |
# |
|
|
|
|
|
Protective Effects of Epigallocatechin-3-Gallate from Green Tea in Various Kidney Diseases |
2562 |
# |
|
|
|
|
|
Protective effect of medicinal plants used in cancer prevention by traditional healers in Thailand. |
2559 |
# |
|
|
|
|
|
Protective Effect of Mangosteen Extract against beta-Amyloid-Induced Cytotoxicity, Oxidative Stress and Altered Proteome in SK-N-SH Cells |
2553 |
# |
|
|
|
|
|
Protective effect of epigallocatechin-3-gallate (EGCG) via Nrf2 pathway against oxalate-induced epithelial mesenchymal transition (EMT) of renal tubular cells. |
2559 |
# |
|
|
|
|
|
Protective effect of AVS073, a polyherbal formula, against UVA-induced melanogenesis through a redox mechanism involving glutathione-related antioxidant defense |
2556 |
# |
|
|
|
|
|
Protective Cellular Mechanism of Estrogen Against Kidney Stone Formation: A Proteomics Approach and Functional Validation |
2562 |
# |
|
|
|
|
|
Protection of centrilobular necrosis by Curcuma comosa Roxb. in carbon tetrachloride-induced mice liver injury |
2553 |
# |
|
|
|
|
|
Protection of cell death and sustained tyrosine hydroxylase phosphorylation in hydrogen peroxide treated human neuroblastoma SH-SY5Y cultured cells by melatonin |
2552 |
# |
|
|
|
|
|
Protection against UVA-Induced Melanogenesis by Dietary Phenolics through Nrf2-Mediated Antioxidant Defenses |
2557 |
# |
|
|
|
|
|
Protection against cisplatin-induced nephrotoxicity in mice by Curcuma comosa Roxb. ethanol extract |
2552 |
# |
|
|
|
|
|
Protease inhibitors and avascular necrosis: A systematic review and meta-analysis |
2557 |
# |
|
|
|
|
|
Prosthetics and orthotics education development in Southeast Asia |
2561 |
# |
|
|
|
|
|
Prosthetic valve endocarditis caused by Histoplasma capsulatum: The first case report in Thailand |
2556 |
# |
|
|
|
|
|
PROSTHETIC JOINT INFECTION DEU TO MYCOBACTERIUM TUBERCULOSIS |
2559 |
# |
|
|
|
|
|
Prostatic Arterial Embolization for Control of Hematuria in Patients with Advanced Prostate Cancer. |
2560 |
# |
|
|
|
|
|
Prostaglandin E-2-prostoglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression |
2554 |
# |
|
|
|
|
|
Prospects for proteomics in kidney stone disease. |
2560 |
# |
|
|
|
|
|
Prospective, randomized comparison of castor oil and sodium phosphate preparation for barium enema. |
2552 |
# |
|
|
|
|
|
Prospective, Randomized Assessment of HBV-Associated and Other Clinical Outcome Events During Long-Term Therapy With Entecavir or Other HBV Nucleos(t)ide Analogues in Patients With Chronic HBV Infection |
2560 |
# |
|
|
|
|
|
Prospective validation of the Emergency Surgery Score (ESS) in Emergency General Surgery: An EAST Multicenter Study. |
2563 |
# |
|
|
|
|
|
Prospective study of ventilator-associated pneumonia in a postoperative intensive care unit |
2545 |
# |
|
|
|
|
|
Prospective study of Q-switched Nd:YAG laser treatment of hyperpigmented split-thickness skin grafts |
2565 |
# |
|
|
|
|
|
Prospective study of hypotension and bradycardia during spinal anesthesia with bupivacaine: incidence and risk factors, part two. |
2550 |
# |